Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 29;38(1):13-24.
doi: 10.4103/sjopt.sjopt_256_23. eCollection 2024 Jan-Mar.

Monoclonal antibodies in neuro-ophthalmology

Caroline C Keehn  1 , Arman Yazdian  1 , Patrick J Hunt  1 , Pamela Davila-Siliezar  2 , Noor A Laylani  2 , Andrew G Lee  1   2   3   4   5   6   7   8
Affiliations

Monoclonal antibodies in neuro-ophthalmology

Caroline C Keehn et al. Saudi J Ophthalmol. .

Abstract

Neuro-ophthalmologic diseases include a broad range of disorders affecting the afferent and efferent visual pathways. Recently, monoclonal antibody (mAb) therapies have emerged as a promising targeted approach in the management of several of these complex conditions. Here, we describe the mechanism-specific applications and advancements in neuro-ophthalmologic mAb therapies. The application of mAbs in neuro-ophthalmologic diseases highlights our increasing understanding of disease-specific mechanisms in autoimmune conditions such as neuromyelitis optica, thyroid eye disease, and myasthenia gravis. Due to the specificity of mAb therapies, applications in neuro-ophthalmologic diseases have yielded exceptional clinical outcomes, including both reduced rate of relapse and progression to disability, visual function preservation, and quality of life improvement. These advancements have not only expanded the range of treatable neuro-ophthalmologic diseases but also reduced adverse events and increased the response rate to treatment. Further research into neuro-ophthalmologic disease mechanisms will provide accurate and specific targeting of important disease mediators through applications of future mAbs. As our understanding of these diseases and the relevant therapeutic targets evolve, we will continue to build on our understanding of how mAbs interfere with disease pathogenesis, and how these changes improve clinical outcomes and quality of life for patients.

Keywords: Biologicals; giant cell arteritis; myasthenia gravis; neuromyelitis optica; thyroid eye disease.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

See all similar articles

References

    1. Kaunitz JD. Development of monoclonal antibodies:The dawn of mAb rule. Dig Dis Sci. 2017;62:831–2. - PMC - PubMed
    1. Köhler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976;6:511–9. - PubMed
    1. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7:e00535. - PMC - PubMed
    1. World Health Organization (WHO) International Nonproprietary Names (INN) for Biological and Biotechnological Substances (A Review) World Health Organization; 2014. pp. 8–10.
    1. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L. Monoclonal antibody therapeutics:History and future. Curr Opin Pharmacol. 2012;12:615–22. - PubMed
-